Noopept (GVS-111, omberacetam) is a synthetic peptide-derived nootropic developed in 1996 at the Russian Academy of Medical Sciences. Though often grouped with racetams due to similar effects, it is structurally a dipeptide analog of piracetam with a prolyl-glycine backbone. Noopept is estimated to be 1000 times more potent than piracetam on a per-milligram basis, with effective doses in the 10-30 mg range. It enhances BDNF and NGF expression, modulates AMPA and NMDA receptors, and has demonstrated neuroprotective and anxiolytic properties. It is prescribed in Russia for cognitive disorders and is widely used globally as a nootropic supplement.
Harm Reduction
Standard dose is 10-30 mg taken sublingually or orally, one to three times daily. Start with 10 mg to assess response. Sublingual administration provides faster onset (5-15 minutes vs 30-60 minutes or...
Read full harm reduction guide